Amy Huang, PharmD, RPh, currently serves as the US Medical Director for Nemolizumab at Galderma since April 2024. Prior experience includes the role of Associate Medical Director for US Medical Affairs in Rare Diseases at Alnylam Pharmaceuticals from August 2023 to May 2024, as well as a tenure at Chiesi USA, Inc. where responsibilities encompassed Associate Director positions in Scientific Publications & Communications and Medical Information & Communications for Rare Hematology & Immunology and Global Rare Diseases from January 2021 to August 2023. Additional professional experience includes positions at Catabasis Pharmaceuticals, Sanofi Genzyme, Verastem Oncology, Ironwood Pharmaceuticals, Cambridge Health Alliance, Sanofi, and the FDA. Amy holds a Doctor of Pharmacy (PharmD) degree from Northeastern University, obtained in 2018, and a Bachelor of Science (BS) in Pharmacy Studies with a minor in Business Administration from the same institution, completed in 2017.
This person is not in any teams
This person is not in any offices